Shanghai Novamab Biopharmaceuticals Co., Ltd.

Xiaoning Shen

Yakun Wan

Min Zhu

Junwei Gai

Disclosed is an anti-IL-4R single-domain antibody and the use thereof. In particular, disclosed are a IL-4R single-domain antibody and a VHH chain thereof, a coding sequence encoding the above-mentioned single-domain antibody or the VHH chain thereof, a corresponding expression vector, host cells capable of expressing the single-domain antibody, and a method for producing the single-domain antibody. The single-domain antibody can specifically recognize human and marmoset IL-4R, but does not recognize mouse IL-4R, and the specificity is good; the single-domain antibody can effectively inhibit the proliferation of TF-1 cells and the activation of a pSTAT6 signaling pathway in cells.

Anti-interleukin-4 receptor (IL-4R) single-domain antibody, encoding polynucleotide and methods of making and using the antibody for IL-4R detection and disease treatment

Provided are a single-domain antibody against human programmed death-ligand 1 (PD-L1) and application thereof. The PD-L1 binding molecule of the present invention can be used for treating and/or preventing, or diagnosing PD-L1 related diseases such as tumors.

Blocking type PD-L1 single-domain camel antibody and application thereof

A CD47 single-domain antibody and use thereof, and in particularly, a blocking type single-domain antibody for integrin-related protein (CD47) and derivative proteins thereof. In particular, disclosed are an integrin-related protein (CD47) binding molecule and use thereof, particularly in the treatment and/or prevention, or diagnosis of CD47-associated diseases, such as tumors. The CD47 single-domain antibody involved can effectively block the interaction between CD47 and a ligand SIRPa thereof, has good binding activity, blocking activity, affinity and stability, can effectively enhance the phagocytosis of tumor cells by macrophages, and shows significant anti-tumor activity in both a human lymphoma model and a human ovarian cancer model. In addition, the antibody does not cause hemoagglutination in vitro, and shows excellent safety in cynomolgus monkeys.

Growing community of inventors

Shanghai, China

Xiaoning Shen